Sangamo Therapeutics, Inc.
T cell modifying compounds and uses thereof
Last updated:
Abstract:
Methods and compositions for modifying T-cells in which PD1 and/or CTLA-4 is repressed and/or inactivated using fusion proteins such as artificial transcription factors and nucleases.
Status:
Grant
Type:
Utility
Filling date:
8 Mar 2017
Issue date:
1 Feb 2022